Oppenheimer analyst Silvan Tuerkcan raised the price target on Exelixis (NASDAQ: EXEL) to $30.00 (from $27.00) while maintaining an Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Exelixis (EXEL) PT Lowered to $22 at StifelAugust 6, 2021 8:58 AM Exelixis (EXEL) Tops Q2 EPS by 30cAugust 5, 2021 4:25 PM Form 10-Q EXELIXIS, INC. For: Jul 02August 5, 2021 4:22 PM Form 8-K EXELIXIS, INC. For: Aug 05August 5, 2021 4:15 PM Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 5, 2021 4:05 PM Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerAugust 5, 2021 8:01 AM